Axonics (AXNX) Stock Forecast, Price Target & Predictions
AXNX Stock Forecast
Axonics stock forecast is as follows: an average price target of $71.00 (represents a 0.03% upside from AXNX’s last price of $70.98) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
AXNX Price Target
The average price target for Axonics (AXNX) is $71.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $71.00 to $71.00. This represents a potential 0.03% upside from AXNX's last price of $70.98.
AXNX Analyst Ratings
According to 6 Wall Street analysts, Axonics's rating consensus is 'Buy'. The analyst rating breakdown for AXNX stock is 0 'Strong Buy' (0.00%), 4 'Buy' (66.67%), 2 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Axonics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | Adam Maeder | Piper Sandler | $71.00 | $69.31 | 2.44% | 0.03% |
The latest Axonics stock forecast, released on Sep 19, 2024 by Adam Maeder from Piper Sandler, set a price target of $71.00, which represents a 2.44% increase from the stock price at the time of the forecast ($69.31), and a 0.03% increase from AXNX last price ($70.98).
Axonics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $71.00 | $71.00 |
| Last Closing Price | $70.98 | $70.98 | $70.98 |
| Upside/Downside | -100.00% | 0.03% | 0.03% |
In the current month, the average price target of Axonics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Axonics's last price of $70.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Feb 29, 2024 | Wells Fargo | Sector Perform | Sector Perform | Hold |
| Jul 13, 2023 | KeyBanc | Overweight | Initialise | |
| Mar 24, 2023 | Needham | Buy | Upgrade | |
| Oct 05, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 02, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Feb 25, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Feb 25, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
Axonics's last stock rating was published by Piper Sandler on Sep 19, 2024. The company gave AXNX a "Neutral" rating, the same as its previous rate.
Axonics Financial Forecast
Axonics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $93.10M | $22.70M | $70.65M | $85.92M | $70.38M | $68.98M | $48.42M | $53.13M | $46.91M | $45.87M | $34.37M | $34.78M | $35.24M | $15.21M | $26.30M | $9.95M | $1.31M |
| Avg Forecast | $180.99M | $159.71M | $157.36M | $125.39M | $157.34M | $137.31M | $135.69M | $108.46M | $128.89M | $113.36M | $112.83M | $89.79M | $107.33M | $89.59M | $86.45M | $64.43M | $82.22M | $63.54M | $59.60M | $45.37M | $50.37M | $48.39M | $39.82M | $27.94M | $35.29M | $22.95M | $5.19M | $14.64M | $10.00M | $1.42M |
| High Forecast | $182.91M | $161.40M | $159.02M | $126.72M | $159.00M | $138.76M | $137.12M | $109.60M | $130.11M | $113.55M | $112.83M | $89.79M | $107.50M | $89.59M | $87.36M | $65.11M | $83.09M | $63.54M | $59.60M | $45.37M | $50.37M | $48.39M | $39.82M | $27.94M | $35.29M | $22.95M | $5.19M | $14.64M | $10.00M | $1.42M |
| Low Forecast | $178.10M | $157.16M | $154.84M | $123.39M | $154.82M | $135.11M | $133.52M | $106.72M | $127.66M | $113.17M | $112.83M | $89.79M | $107.01M | $89.59M | $85.07M | $63.40M | $80.91M | $63.54M | $59.60M | $45.37M | $50.37M | $48.39M | $39.82M | $27.94M | $35.29M | $22.95M | $5.19M | $14.64M | $10.00M | $1.42M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.04% | 0.26% | 1.10% | 1.04% | 1.11% | 1.16% | 1.07% | 1.05% | 0.97% | 1.15% | 1.23% | 0.99% | 1.54% | 2.93% | 1.80% | 0.99% | 0.92% |
Axonics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $107.33M, with a low forecast of $107.01M, and a high forecast of $107.50M. AXNX's average Quarter revenue forecast represents a 15.29% increase compared to the company's last Quarter revenue of $93.10M (Sep 23).
Axonics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-687.00K | $22.31M | $-8.61M | $2.96M | $-4.32M | $-5.97M | $-20.46M | $-15.11M | $-13.80M | $-13.34M | $-20.48M | $-10.41M | $-8.29M | $-18.91M | $-13.68M | $-21.88M | $-24.11M |
| Avg Forecast | $-70.71M | $-62.40M | $-61.48M | $-48.99M | $-61.47M | $-53.64M | $-53.01M | $-42.37M | $-50.36M | $-44.29M | $-44.08M | $-29.87M | $-41.93M | $-35.00M | $-33.77M | $-27.15M | $-17.97M | $-23.97M | $-22.49M | $-24.68M | $-19.01M | $-18.26M | $-15.03M | $-12.48M | $-13.32M | $-8.66M | $-1.96M | $-17.56M | $-3.77M | $-534.80K |
| High Forecast | $-69.58M | $-61.40M | $-60.50M | $-48.21M | $-60.49M | $-52.79M | $-52.16M | $-41.70M | $-49.88M | $-44.22M | $-44.08M | $-23.89M | $-41.81M | $-35.00M | $-33.23M | $-21.72M | $-14.38M | $-23.97M | $-22.49M | $-19.75M | $-19.01M | $-18.26M | $-15.03M | $-9.99M | $-13.32M | $-8.66M | $-1.96M | $-14.05M | $-3.77M | $-534.80K |
| Low Forecast | $-71.46M | $-63.06M | $-62.13M | $-49.51M | $-62.12M | $-54.21M | $-53.57M | $-42.82M | $-50.83M | $-44.36M | $-44.08M | $-35.84M | $-42.00M | $-35.00M | $-34.13M | $-32.58M | $-21.57M | $-23.97M | $-22.49M | $-29.62M | $-19.01M | $-18.26M | $-15.03M | $-14.98M | $-13.32M | $-8.66M | $-1.96M | $-21.07M | $-3.77M | $-534.80K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.02% | -0.66% | 0.32% | -0.16% | 0.18% | 0.27% | 0.83% | 0.80% | 0.76% | 0.89% | 1.64% | 0.78% | 0.96% | 9.66% | 0.78% | 5.80% | 45.08% |
4 analysts predict AXNX's average Quarter EBITDA for Sep 23 to be $-35.00M, with a high of $-35.00M and a low of $-35.00M. This is -256.91% lower than Axonics's previous annual EBITDA (Jun 23) of $22.31M.
Axonics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.93M | $-7.34M | $-9.25M | $665.00K | $-16.25M | $-21.44M | $-22.67M | $-15.17M | $-17.25M | $-25.15M | $-22.50M | $-11.35M | $-9.17M | $-19.78M | $-14.62M | $-22.75M | $-25.01M |
| Avg Forecast | $21.59M | $11.99M | $12.08M | $-1.54M | $15.07M | $8.17M | $14.65M | $-2.38M | $14.56M | $5.74M | $5.02M | $-33.09M | $3.30M | $-2.61M | $-6.02M | $-30.08M | $-18.04M | $-23.84M | $-28.10M | $-27.35M | $-18.41M | $-21.94M | $-25.15M | $-13.72M | $-15.82M | $-26.88M | $-33.27M | $-18.76M | $-36.68M | $-38.28M |
| High Forecast | $21.89M | $12.15M | $12.25M | $-1.51M | $15.28M | $8.29M | $14.85M | $6.56M | $20.69M | $5.97M | $5.02M | $-26.47M | $5.49M | $-2.55M | $-5.89M | $-24.06M | $-14.43M | $-23.84M | $-28.10M | $-21.88M | $-18.41M | $-21.94M | $-25.15M | $-10.98M | $-15.82M | $-26.88M | $-33.27M | $-15.01M | $-36.68M | $-38.28M |
| Low Forecast | $21.15M | $11.74M | $11.83M | $-1.56M | $14.76M | $8.00M | $14.34M | $-8.94M | $9.96M | $5.50M | $5.01M | $-39.71M | $1.10M | $-2.64M | $-6.10M | $-36.10M | $-21.64M | $-23.84M | $-28.10M | $-32.81M | $-18.41M | $-21.94M | $-25.15M | $-16.47M | $-15.82M | $-26.88M | $-33.27M | $-22.51M | $-36.68M | $-38.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.51% | 1.22% | 0.31% | -0.04% | 0.68% | 0.76% | 0.83% | 0.82% | 0.79% | 1.00% | 1.64% | 0.72% | 0.34% | 0.59% | 0.78% | 0.62% | 0.65% |
Axonics's average Quarter net income forecast for Dec 23 is $3.30M, with a range of $1.10M to $5.49M. AXNX's average Quarter net income forecast represents a -16.10% decrease compared to the company's last Quarter net income of $3.93M (Sep 23).
Axonics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $59.32M | $54.98M | $54.82M | $54.09M | $49.14M | $49.95M | $43.08M | $40.74M | $36.83M | $33.45M | $27.55M | $24.87M | $22.83M | $19.76M | $24.22M | $21.84M | $20.87M |
| Avg Forecast | $284.23M | $250.82M | $247.12M | $196.92M | $247.09M | $215.63M | $213.09M | $170.33M | $202.41M | $178.03M | $177.20M | $62.88M | $168.56M | $140.70M | $135.76M | $57.16M | $48.45M | $99.78M | $93.60M | $71.25M | $79.10M | $75.99M | $62.54M | $16.80M | $55.42M | $36.04M | $8.15M | $22.99M | $15.70M | $2.23M |
| High Forecast | $287.24M | $253.47M | $249.73M | $199.00M | $249.70M | $217.91M | $215.34M | $172.12M | $204.33M | $178.32M | $177.20M | $75.45M | $168.82M | $140.70M | $137.19M | $68.59M | $58.14M | $99.78M | $93.60M | $71.25M | $79.10M | $75.99M | $62.54M | $20.16M | $55.42M | $36.04M | $8.15M | $22.99M | $15.70M | $2.23M |
| Low Forecast | $279.69M | $246.81M | $243.17M | $193.77M | $243.14M | $212.18M | $209.68M | $167.60M | $200.48M | $177.73M | $177.20M | $50.30M | $168.05M | $140.70M | $133.59M | $45.73M | $38.76M | $99.78M | $93.60M | $71.25M | $79.10M | $75.99M | $62.54M | $13.44M | $55.42M | $36.04M | $8.15M | $22.99M | $15.70M | $2.23M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.42% | 0.41% | 0.96% | 1.12% | 0.49% | 0.53% | 0.60% | 0.52% | 0.48% | 0.53% | 1.64% | 0.45% | 0.63% | 2.42% | 1.05% | 1.39% | 9.38% |
Axonics's average Quarter SG&A projection for Dec 23 is $168.56M, based on 8 Wall Street analysts, with a range of $168.05M to $168.82M. The forecast indicates a 184.14% rise compared to AXNX last annual SG&A of $59.32M (Sep 23).
Axonics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 5 | 4 | 8 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 5 | 4 | 5 | 4 | 5 | 4 | 5 | 4 | 4 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.08 | $-0.15 | $-0.19 | $0.01 | $-0.34 | $-0.47 | $-0.50 | $-0.34 | $-0.38 | $-0.59 | $-0.57 | $-0.29 | $-0.24 | $-0.54 | $-0.43 | $-0.75 | $-0.89 |
| Avg Forecast | $0.42 | $0.23 | $0.24 | $-0.03 | $0.29 | $0.16 | $0.29 | $-0.05 | $0.28 | $0.11 | $0.10 | $-0.06 | $0.06 | $-0.05 | $-0.12 | $-0.29 | $-0.24 | $-0.47 | $-0.55 | $-0.63 | $-0.36 | $-0.43 | $-0.49 | $-0.41 | $-0.31 | $-0.52 | $-0.65 | $-0.60 | $-0.72 | $-0.75 |
| High Forecast | $0.43 | $0.24 | $0.24 | $-0.03 | $0.30 | $0.16 | $0.29 | $0.13 | $0.41 | $0.12 | $0.10 | $-0.06 | $0.11 | $-0.05 | $-0.12 | $-0.28 | $-0.23 | $-0.47 | $-0.55 | $-0.63 | $-0.36 | $-0.43 | $-0.49 | $-0.41 | $-0.31 | $-0.52 | $-0.65 | $-0.60 | $-0.72 | $-0.75 |
| Low Forecast | $0.41 | $0.23 | $0.23 | $-0.03 | $0.29 | $0.16 | $0.28 | $-0.17 | $0.20 | $0.11 | $0.10 | $-0.06 | $0.02 | $-0.05 | $-0.12 | $-0.29 | $-0.24 | $-0.47 | $-0.55 | $-0.63 | $-0.36 | $-0.43 | $-0.49 | $-0.41 | $-0.31 | $-0.52 | $-0.65 | $-0.60 | $-0.72 | $-0.75 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.56% | 1.27% | 0.66% | -0.04% | 0.73% | 0.86% | 0.79% | 0.95% | 0.89% | 1.20% | 1.40% | 0.94% | 0.46% | 0.83% | 0.72% | 1.05% | 1.19% |
According to 8 Wall Street analysts, Axonics's projected average Quarter EPS for Dec 23 is $0.06, with a low estimate of $0.02 and a high estimate of $0.11. This represents a -19.16% decrease compared to AXNX previous annual EPS of $0.08 (Sep 23).
Axonics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| NNOX | Nano-X Imaging | $7.31 | $18.00 | 146.24% | Buy |
| LUNG | Pulmonx | $6.13 | $13.00 | 112.07% | Buy |
| KIDS | OrthoPediatrics | $22.46 | $39.50 | 75.87% | Buy |
| LIVN | LivaNova | $49.94 | $68.25 | 36.66% | Buy |
| BRKR | Bruker | $57.81 | $79.00 | 36.65% | Buy |
| CNMD | CONMED | $71.23 | $97.00 | 36.18% | Buy |
| OFIX | Orthofix Medical | $17.93 | $24.00 | 33.85% | |
| SIBN | SI-BONE | $13.84 | $18.50 | 33.67% | Buy |
| NPCE | NeuroPace | $11.52 | $15.00 | 30.21% | Buy |
| IRTC | iRhythm | $91.45 | $111.38 | 21.79% | Buy |
| MDT | Medtronic | $81.37 | $95.40 | 17.24% | Hold |
| ITGR | Integer | $136.68 | $153.50 | 12.31% | Buy |
| AXNX | Axonics | $70.98 | $71.00 | 0.03% | Buy |
| IART | Integra LifeSciences | $23.03 | $23.00 | -0.13% | Sell |
| GKOS | Glaukos | $146.35 | $144.14 | -1.51% | Buy |